John M. Koerber

507 total citations
18 papers, 347 citations indexed

About

John M. Koerber is a scholar working on Surgery, Internal Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John M. Koerber has authored 18 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 12 papers in Internal Medicine and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John M. Koerber's work include Heparin-Induced Thrombocytopenia and Thrombosis (12 papers), Venous Thromboembolism Diagnosis and Management (12 papers) and Acute Myocardial Infarction Research (6 papers). John M. Koerber is often cited by papers focused on Heparin-Induced Thrombocytopenia and Thrombosis (12 papers), Venous Thromboembolism Diagnosis and Management (12 papers) and Acute Myocardial Infarction Research (6 papers). John M. Koerber collaborates with scholars based in United States and New Zealand. John M. Koerber's co-authors include Maureen A. Smythe, Joan C. Mattson, Robert L. Begle, M. Balasubramaniam, Jennifer L. Stephens, Maureen H. Fitzgerald, Elizabeth A. Bertran, Rajul Parikh, Elizabeth Sykes and Anant Krishnan and has published in prestigious journals such as Blood, CHEST Journal and Thrombosis and Haemostasis.

In The Last Decade

John M. Koerber

18 papers receiving 335 citations

Peers

Countries citing papers authored by John M. Koerber

Since Specialization

Citations

This map shows the geographic impact of John M. Koerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Koerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Koerber more than expected).

Fields of papers citing papers by John M. Koerber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Koerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Koerber. The network helps show where John M. Koerber may publish in the future.

Co-authorship network of co-authors of John M. Koerber

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Koerber. A scholar is included among the top collaborators of John M. Koerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Koerber. John M. Koerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Hospital Acquired Venous Thromboembolism: A Preventability Assessment 2023 ·Hospital Pharmacy ·Maureen A. Smythe, John M. Koerber, Amanda Roberts, (unknown), (unknown)	2
2	Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding 2021 ·Thrombosis Research ·Maureen A. Smythe, John M. Koerber, (unknown), (unknown), (unknown), (unknown), (unknown), Anant Krishnan	3
3	Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes 2018 ·Hospital Practice ·(unknown), (unknown), (unknown), John M. Koerber, Maureen A. Smythe	2
4	Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban 2016 ·Clinical and Applied Thrombosis/Hemostasis ·(unknown), (unknown), (unknown), John M. Koerber, Maureen A. Smythe	6
5	Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients 2015 ·Journal of Thrombosis and Thrombolysis ·Maureen A. Smythe, (unknown), Elizabeth A. Bertran, (unknown), (unknown), John M. Koerber	17
6	Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost 2012 ·Thrombosis and Haemostasis ·John M. Koerber, (unknown), (unknown), (unknown), (unknown), Joan C. Mattson, Maureen A. Smythe	7
7	Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol 2012 ·American Journal of Health-System Pharmacy ·Maureen A. Smythe, (unknown), John M. Koerber, (unknown), Elizabeth Sykes, (unknown), (unknown), Rajul Parikh	10
8	Argatroban Dosage Requirements and Outcomes in Intensive Care versus Non‐Intensive Care Patients 2009 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Maureen A. Smythe, John M. Koerber, (unknown), (unknown), M. Balasubramaniam, Joan C. Mattson	22
9	The Financial Impact of Heparin-Induced Thrombocytopenia 2008 ·CHEST Journal ·Maureen A. Smythe, John M. Koerber, Maureen H. Fitzgerald, Joan C. Mattson	28
10	The Incidence of Recognized Heparin-Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital 2007 ·CHEST Journal ·Maureen A. Smythe, John M. Koerber, Joan C. Mattson	116
11	Capturing the Financial Impact of Heparin-Induced Thrombocytopenia. 2005 ·Blood ·Maureen A. Smythe, John M. Koerber, Joan C. Mattson	1
12	A Comparison of Lepirudin and Argatroban Outcomes 2005 ·Clinical and Applied Thrombosis/Hemostasis ·Maureen A. Smythe, Jennifer L. Stephens, John M. Koerber, Joan C. Mattson	28
13	Effect of Lepirudin on the International Normalized Ratio 2004 ·Annals of Pharmacotherapy ·Jennifer L. Stephens, John M. Koerber, Joan C. Mattson, Maureen A. Smythe	7
14	Comparing Methods of Establishing the aPTT Therapeutic Range of Heparin 2003 ·Annals of Pharmacotherapy ·(unknown), John M. Koerber, Joan C. Mattson, (unknown), Maureen A. Smythe	4
15	Correlation Between Activated Clotting Time and Activated Partial Thromboplastin Times 2002 ·Annals of Pharmacotherapy ·Maureen A. Smythe, John M. Koerber, (unknown), Joan C. Mattson, Robert L. Begle, (unknown), M. Balasubramaniam	2
16	Correlation between Activated Clotting Time and Activated Partial Thromboplastin Times 2002 ·Annals of Pharmacotherapy ·Maureen A. Smythe, John M. Koerber, (unknown), Joan C. Mattson, Robert L. Begle, (unknown), M. Balasubramaniam	33
17	Use of the Activated Partial Thromboplastin Time for Heparin Monitoring 2001 ·American Journal of Clinical Pathology ·Maureen A. Smythe, John M. Koerber, (unknown), (unknown), Robert L. Begle, M. Balasubramaniam, Joan C. Mattson	21
18	Correlation of Activated Clotting Time and Activated Partial Thromboplastin Time to Plasma Heparin Concentration 1999 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·John M. Koerber, Maureen A. Smythe, Robert L. Begle, Joan C. Mattson, (unknown), (unknown)	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact